Atherosclerotic coronary plaque regression and the risk of adverse cardiovascular events: A meta-regression of randomized clinical trials

Atherosclerosis

Volumn 226, Issue 1, 2013, Pages 178-185

  D'Ascenzo, Fabrizio ^a   Agostoni, Pierfrancesco ^c   Abbate, Antonio ^d,e   Castagno, Davide ^a   Lipinski, Michael J ^d,e   Vetrovec, George W ^d,e   Frati, Giacomo ^b   Presutti, Davide Giacomo ^a   Quadri, Giorgio ^a   Moretti, Claudio ^a   Gaita, Fiorenzo ^a   Zoccai, Giuseppe Biondi ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Clinical events; IVUS plaque volume; Reduction of atherosclerosis plaque volume

Indexed keywords

ARTICLE; ATHEROSCLEROTIC CORONARY PLAQUE; BIBLIOGRAPHIC DATABASE; BIOMED CENTRAL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; CENTRAL; CORONARY ARTERY ATHEROSCLEROSIS; DEATH; DISEASE ASSOCIATION; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; IMAGE ANALYSIS; INTRAVASCULAR ULTRASOUND; MEDLINE; META ANALYSIS; PERCENTAGE OF ATHEROMA VOLUME; PRIORITY JOURNAL; REMISSION; RISK ASSESSMENT; SYSTEMATIC REVIEW;

CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; HUMANS; PLAQUE, ATHEROSCLEROTIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84871374600     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.10.065     Document Type: Article

References (81)

1. Huisman J., Böse D., Jensen L.O., et al. Serial intravascular ultrasound assessment of changes in coronary atherosclerotic plaque dimensions and composition: an update. Eur J Echocardiogr 2011 Apr, 12(4):313-321.
2. Kern M.J., Meier B. Evaluation of the culprit plaque and the physiological significance of coronary atherosclerotic narrowings. Circulation 2001 Jun 26, 103(25):3142-3149.
3. Tardif J.C., Grégoire J., L'Allier P.L. Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial. Atherosclerosis 2008 Mar, 197(1):480-486.
4. Tardif J.C., Grégoire J., L'Allier P.L., et al. Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation 2004 Nov 23, 110(21):3372-3377. Avasimibe and Progression of Lesions on UltraSound (A-PLUS) Investigators.
5. Nissen S.E., Nicholls S.J., Wolski K., et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. J Am Med Assoc 2008 Apr 2, 299(13):1561-1573. PERISCOPE Investigators.
6. Hirohata A., Yamamoto K., Miyoshi T., et al. Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial. J Am Coll Cardiol 2010 Mar 9, 55(10):976-982.
7. Fayad Z.A., Mani V., Fuster V. The time has come for clinical cardiovascular trials with plaque characterization as an endpoint. Eur Heart J 2012 Jan, 33(2):160-161. Epub 2011 Aug 28.
8. Biondi-Zoccai G., Sheiban I., Romagnoli E., et al. Is intravascular ultrasound beneficial for percutaneous coronary intervention of bifurcation lesions? Evidence from a 4,314-patient registry. Clin Res Cardiol 2011 Nov, 100(11):1021-1028.
9. Rodriguez-Granillo G.A., Vaina S., García-García H.M., et al. Reproducibility of intravascular ultrasound radiofrequency data analysis: implications for the design of longitudinal studies. Int J Cardiovasc Imaging 2006 Oct, 22(5):621-631.
10. Yokoyama M., Komiyama N., Courtney B.K., et al. Plasma low-density lipoprotein reduction and structural effects on coronary atherosclerotic plaques by atorvastatin as clinically assessed with intravascular ultrasound radio-frequency signal analysis: a randomized prospective study. Am Heart J 2005 Aug, 150(2):287.
11. Moher D., Liberati A., Tetzlaff J., et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009 Jul 21, 339:b2535. PRISMA Group. 10.1136/bmj.b2535.
12. Moher D., Cook D.J., Eastwood S., et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 1999 Nov 27, 354(9193):1896-1900.
13. Cochrane handbook for systematic reviews of interventions version 5.0.2 2009, The Cochrane Collaboration, [updated September 2009]. Available from:. http://www.cochrane-handbook.org, J.P.T. Higgins, S. Green (Eds.).
14. Biondi-Zoccai G.G., Abbate A., Agostoni P., et al. Long-term benefits of an early invasive management in acute coronary syndromes depend on intracoronary stenting and aggressive antiplatelet treatment: a metaregression. Am Heart J 2005 Mar, 149(3):504-511.
15. Yamada T., Azuma A., Sasaki S., et al. Randomized evaluation of atorvastatin in patients with coronary heart disease: a serial intravascular ultrasound study. Circ J 2007 Dec, 71(12):1845-1850. REACH Study Group.
16. Takarada S., Imanishi T., Ishibashi K., et al. The effect of lipid and inflammatory profiles on the morphological changes of lipid-rich plaques in patients with non-ST-segment elevated acute coronary syndrome: follow-up study by optical coherence tomography and intravascular ultrasound. JACC Cardiovasc Interv 2010 Jul, 3(7):766-772.
17. Waseda K., Ozaki Y., Takashima H., et al. Impact of angiotensin II receptor blockers on the progression and regression of coronary atherosclerosis: an intravascular ultrasound study. Circ J 2006 Sep, 70(9):1111-1115.
18. Wakeyama T., Ogawa H., Iida H., et al. Effects of candesartan and probucol on restenosis after coronary stenting: results of insight of stent intimal hyperplasia inhibition by new angiotensin II receptor antagonist (ISHIN) trial. Circ J 2003 Jun, 67(6):519-524.
19. von Birgelen C., Hartmann M., Mintz G.S., et al. Relation between progression and regression of atherosclerotic left main coronary artery disease and serum cholesterol levels as assessed with serial long-term (> or =12 months) follow-up intravascular ultrasound. Circulation 2003 Dec 2, 108(22):2757-2762.
20. Tsuchikane E., Katoh O., Sumitsuji S., et al. Impact of cilostazol on intimal proliferation after directional coronary atherectomy. Am Heart J 1998 Mar, 135(3):495-502.
21. Toi T., Taguchi I., Yoneda S., et al. Early effect of lipid-lowering therapy with pitavastatin on regression of coronary atherosclerotic plaque. Comparison with atorvastatin. Circ J 2009 Aug, 73(8):1466-1472.
22. Tani S., Nagao K., Anazawa T., et al. Coronary plaque regression and lifestyle modification in patients treated with pravastatin - assessment mainly by daily aerobic exercise and an increase in the serum level of high-density lipoprotein cholesterol. Circ J 2010 May, 74(5):954-961.
23. Tani S., Nagao K., Anazawa T., et al. Association of leukocyte subtype counts with coronary atherosclerotic regression following pravastatin treatment. Am J Cardiol 2009 Aug 15, 104(4):464-469.
24. Tani S., Nagao K., Anazawa T., et al. Association of body mass index with coronary plaque regression: 6-month prospective study. J Atheroscler Thromb 2009 Jun, 16(3):275-282.
25. Takashima H., Ozaki Y., Yasukawa T., et al. Impact of lipid-lowering therapy with pitavastatin, a new HMG-CoA reductase inhibitor, on regression of coronary atherosclerotic plaque. Circ J 2007 Nov, 71(11):1678-1684.
26. Arai H., Hiro T., Kimura T., et al. More intensive lipid lowering is associated with regression of coronary atherosclerosis in diabetic patients with acute coronary syndrome - sub-analysis of JAPAN-ACS study. J Atheroscler Thromb 2010 Oct 27, 17(10):1096-1107.
27. Ballantyne C.M., Raichlen J.S., Nicholls S.J., et al. Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. Circulation 2008 May 13, 117(19):2458-2466.
28. Hong Y.J., Jeong M.H., Choi Y.H., et al. Usual dose of simvastatin does not inhibit plaque progression and lumen loss at the peri-stent reference segments after bare-metal stent implantation: a serial intravascular ultrasound analysis. Korean J Intern Med 2010 Dec, 25(4):356-363.
29. Iwata A., Miura S., Morii J., et al. Association between plasma pigment epithelium-derived factor levels and tissue characteristics of coronary plaque using integrated backscatter intravascular ultrasound. Intern Med 2011, 50(18):1889-1894. Epub 2011 Sep 15.
30. Jensen L.O., Thayssen P., Pedersen K.E., et al. Regression of coronary atherosclerosis by simvastatin: a serial intravascular ultrasound study. Circulation 2004 Jul 20, 110(3):265-270.
31. Kornowski R., Mintz G.S., Lansky A.J., et al. Paradoxic decreases in atherosclerotic plaque mass in insulin-treated diabetic patients. Am J Cardiol 1998 Jun 1, 81(11):1298-1304.
32. Kovarnik T., Mintz G.S., Skalicka H., et al. Virtual histology evaluation of atherosclerosis regression during atorvastatin and ezetimibe administration. Circ J 2011 Dec 22, 76(1):176-183.
33. Nakayama T., Komiyama N., Yokoyama M., et al. Pioglitazone induces regression of coronary atherosclerotic plaques in patients with type 2 diabetes mellitus or impaired glucose tolerance: a randomized prospective study using intravascular ultrasound. Int J Cardiol 2010 Jan 21, 138(2):157-165. Epub 2008 Sep 24.
34. Hong M.K., Mintz G.S., Lee C.W., et al. Serial intravascular ultrasound evidence of both plaque stabilization and lesion progression inpatients with ruptured coronary plaques: effects of statin therapy on ruptured coronary plaque. Atherosclerosis 2007 Mar, 191(1):107-114.
35. Nicholls S.J., Tuzcu E.M., Brennan D.M., et al. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation 2008 Dec 9, 118(24):2506-2514.
36. Nicholls S.J., Tuzcu E.M., Sipahi I., et al. Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano. J Am Coll Cardiol 2006 Mar 7, 47(5):992-997.
37. Nicholls S.J., Tuzcu E.M., Sipahi I., et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. J Am Med Assoc 2007 Feb 7, 297(5):499-508.
38. Nissen S.E., Tsunoda T., Tuzcu E.M., et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. J Am Med Assoc 2003 Nov 5, 290(17):2292-2300.
39. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005 Jan 6, 352(1):29-38.
40. Nissen S.E., Nicholls S.J., Sipahi I., et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. J Am Med Assoc 2006 Apr 5, 295(13):1556-1565.
41. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial.
42. Ogasawara D., Shite J., Shinke T., et al. Pioglitazone reduces the necrotic-core component in coronary plaque in association with enhanced plasma adiponectin in patients with type 2 diabetes mellitus. Circ J 2009 Feb, 73(2):343-351.
43. Otagiri K., Tsutsui H., Kumazaki S., et al. Early intervention with rosuvastatin decreases the lipid components of the plaque in acute coronary syndrome: analysis using integrated backscatter IVUS (ELAN study). Circ J 2011, 75(3):633-634.
44. Brener S.J., Ivanc T.B., Poliszczuk R., et al. Antihypertensive therapy and regression of coronary artery disease: insights from the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis (CAMELOT) and Norvasc for Regression of Manifest Atherosclerotic Lesions by Intravascular Sonographic Evaluation (NORMALISE) trials. Am Heart J 2006 Dec, 152(6):1059-1063.
45. Takayama T., Hiro T., Yamagishi M., et al. Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Circ J 2009 Nov, 73(11):2110-2117. Epub 2009 Oct 5.
46. Hong M.K., Park D.W., Lee C.W., et al. Effects of statin treatments on coronary plaques assessed by volumetric virtual histology intravascular ultrasound analysis. JACC Cardiovasc Interv 2009 Jul, 2(7):679-688.
47. Kawasaki M., Sano K., Okubo M., et al. Volumetric quantitative analysis of tissue characteristics of coronary plaques after statin therapy using three-dimensional integrated backscatter intravascular ultrasound. J Am Coll Cardiol 2005 Jun 21, 45(12):1946-1953.
48. Clementi F., Di Luozzo M., Mango R., et al. Regression and shift in composition of coronary atherosclerotic plaques by pioglitazone: insight from an intravascular ultrasound analysis. J Cardiovasc Med (Hagerstown) 2009 Mar, 10(3):231-237.
49. Hibi K., Kimura T., Kimura K., et al. Clinically evident polyvascular disease and regression of coronary atherosclerosis after intensive statin therapy in patients with acute coronary syndrome: serial intravascular ultrasound from the Japanese Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome (JAPAN-ACS) trial. Atherosclerosis 2011 Dec, 219(2):743-749. Epub 2011 Aug 22.
50. Hirayama A., Saito S., Ueda Y., et al. Qualitative and quantitative changes in coronary plaque associated with atorvastatin therapy. Circ J 2009 Apr, 73(4):718-725. Epub 2009 Feb 18.
51. Hirayama A., Saito S., Ueda Y., et al. Plaque-stabilizing effect of atorvastatin is stronger for plaques evaluated as more unstable by angioscopy and intravenous ultrasound. Circ J 2011, 75(6):1448-1454. Epub 2011 Apr 19.
52. Hiro T., Kimura T., Morimoto T., Miyauchi K., et al. Diabetes mellitus is a major negative determinant of coronary plaque regression during statin therapy in patients with acute coronary syndrome-serial intravascular ultrasound observations from the Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome Trial (the JAPAN-ACS Trial). Circ J 2010 Jun, 74(6):1165-1174. Epub 2010 May 12.
53. Takagi T., Yoshida K., Akasaka T., et al. Intravascular ultrasound analysis of reduction in progression of coronary narrowing by treatment with pravastatin. Am J Cardiol 1997 Jun 15, 79(12):1673-1676.
54. Tardif J.C., Grégoire J., L'Allier P.L., et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. J Am Med Assoc 2007 Apr 18, 297(15):1675-1682.
55. Kojima T., Miyauchi K., Yokoyama T., et al. Azelnidipine and amlodipine anti-coronary atherosclerosis trial in hypertensive patients undergoing coronary intervention by serial volumetric intravascular ultrasound analysis in Juntendo University (ALPS-J). Circ J 2011, 75(5):1071-1079. Epub 2011 Apr 7.
56. Schartl M., Bocksch W., Koschyk D.H., et al. of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation 2001 Jul 24, 104(4):387-392.
57. Lüscher T.F., Pieper M., Tendera M., et al. A randomized placebo-controlled study on the effect of nifedipine on coronary endothelial function and plaque formation in patients with coronary artery disease: the ENCORE II study. Eur Heart J 2009 Jul, 30(13):1590-1597.
58. Hiro T., Kimura T., Morimoto T., et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan Assessment of Pitavastatin And Atorvastatin in Acute Coronary Syndrome] study). J Am Coll Cardiol 2009 Jul 21, 54(4):293-302.
59. Nicholls S.J., Ballantyne C.M., Barter P.J., et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 2011 Dec 1, 365(22):2078-2087.
60. Nissen S.E., Tuzcu E.M., Brewer H.B., et al. Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med 2006 Mar 23, 354(12):1253-1263.
61. Nissen S.E., Nicholls S.J., Wolski K., et al. obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. J Am Med Assoc 2008 Apr 2, 299(13):1547-1560.
62. Nissen S.E., Tuzcu E.M., Libby P., et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. J Am Med Assoc 2004 Nov 10, 292(18):2217-2225. CAMELOT Investigators.
63. Nissen S.E., Tardif J.C., Nicholls S.J., et al. ILLUSTRATE Investigators. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007 Mar 29, 356(13):1304-1316.
64. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. J Am Med Assoc 2004 Mar 3, 291(9):1071-1080. REVERSAL Investigators.
65. Rodriguez-Granillo G.A., de Winter S., Bruining N., et al. Effect of perindopril on coronary remodelling: insights from a multicentre, randomized study. Eur Heart J 2007 Oct, 28(19):2326-2331. EUROPA/PERSPECTIVE Investigators.
66. Okazaki S., Yokoyama T., Miyauchi K., et al. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH study. Circulation 2004 Aug 31, 110(9):1061-1068.
67. Dawber T.R., Meadors G.F., Moore F.E. Epidemiological approaches to heart disease: the Framingham study. Am J Public Health Nations Health 1951, 41:279-281.
68. Jousilahti P., Vartiainen E., Tuomilehto J., et al. Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland. Circulation 1999, 99:1165-1172.
69. Wasserman B.A., Sharrett A.R., Lai S., et al. Risk factor associations with the presence of a lipid core in carotid plaque of asymptomatic individuals using high-resolution MRI: the Multi-Ethnic Study of Atherosclerosis (MESA). Stroke 2008, 39:329-335.
70. Tonstad S., Joakimsen O., Stensland-Bugge E., et al. Risk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolemia and control subjects. Arterioscler Thromb Vasc Biol 1996, 16:984-991.
71. Zheng M., Choi S.Y., Tahk S.J., et al. The relationship between volumetric plaque components and classical cardiovascular risk factors and the metabolic syndrome a 3-vessel coronary artery virtual histology-intravascular ultrasound analysis. JACC Cardiovasc Interv 2011 May, 4(5):503-510.
72. Cliff W.J., Heathcote C.R., Moss N.S., et al. The coronary arteries in cases of cardiac and noncardiac sudden death. Am J Pathol 1988, 132:319-329.
73. Detrano R., Guerci A.D., Carr J.J., et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 2008, 358:1336-1345.
74. Greenland P., LaBree L., Azen S.P., et al. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. J Am Med Assoc 2004, 291:210-215.
75. Nicholls S.J., Hsu A., Wolski K., et al. Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome. J Am Coll Cardiol 2010 May 25, 55(21):2399-2407.
76. von Birgelen C., Hartmann M., Mintz G.S., et al. Relation between progression and regression of atherosclerotic left main coronary artery disease and serum cholesterol levels as assessed with serial long-term (= or >12 months) follow-up intravascular ultrasound. Circulation 2003, 108:2757-2762.
77. Bulbulia R., Bowman L., Wallendszus K., et al. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. Lancet 2011 Dec 10, 378(9808):2013-2020.
78. Nabel E.G., Braunwald E. A tale of coronary artery disease and myocardial infarction. N Engl J Med 2012 Jan 5, 366(1):54-63.
79. Costanzo P., Perrone-Filardi P., Vassallo E., et al. Does carotid intima-media thickness regression predict reduction of cardiovascular events? A meta-analysis of 41 randomized trials. J Am Coll Cardiol 2010 Dec 7, 56(24):2006-2020.
80. Biondi-Zoccai G.G., Lotrionte M., Agostoni P., et al. Benefits of clopidogrel in patients undergoing coronary stenting significantly depend on loading dose: evidence from a meta-regression. Am Heart J 2007 Apr, 153(4):587-593.
81. Morton SC, Adams JL, Suttorp MJ, Shekelle PG. Meta-regression approaches: what, why, when, and how? Technical Reviews, No. 8.